These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9153333)

  • 1. Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and nonscrotal transdermal systems.
    Jordan WP
    Am J Contact Dermat; 1997 Jun; 8(2):108-13. PubMed ID: 9153333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal testosterone delivery: comparison between scrotal and nonscrotal delivery systems.
    Lin S; Xing QF; Chien YW
    Pharm Dev Technol; 1999 Aug; 4(3):405-14. PubMed ID: 10434286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of the contact sensitization potential of a transdermal nicotine system (Nicoderm).
    Jordan WP
    J Fam Pract; 1992 Jun; 34(6):709-12. PubMed ID: 1593244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient satisfaction with testosterone supplementation for the treatment of erectile dysfunction.
    Monga M; Kostelec M; Kamarei M
    Arch Androl; 2002; 48(6):433-42. PubMed ID: 12425760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system.
    Arver S; Dobs AS; Meikle AW; Allen RP; Sanders SW; Mazer NA
    J Urol; 1996 May; 155(5):1604-8. PubMed ID: 8627833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skin tolerability associated with transdermal drug delivery systems: an overview.
    Ale I; Lachapelle JM; Maibach HI
    Adv Ther; 2009 Oct; 26(10):920-35. PubMed ID: 19967501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience using the Androderm testosterone transdermal system in hypogonadal adolescents and young men with beta-thalassemia major.
    De Sanctis V; Vullo C; Urso L; Rigolin F; Cavallini A; Caramelli K; Daugherty C; Mazer N
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():891-900. PubMed ID: 10091163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rates of allergic sensitization and irritation to oxybenzone-containing sunscreen products: a quantitative meta-analysis of 64 exaggerated use studies.
    Agin PP; Ruble K; Hermansky SJ; McCarthy TJ
    Photodermatol Photoimmunol Photomed; 2008 Aug; 24(4):211-7. PubMed ID: 18717962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical management of cutaneous reactions to the methylphenidate transdermal system: recommendations from a dermatology expert panel consensus meeting.
    Warshaw EM; Paller AS; Fowler JF; Zirwas MJ
    Clin Ther; 2008 Feb; 30(2):326-37. PubMed ID: 18343271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product.
    Jordan WP; Atkinson LE; Lai C
    Clin Ther; 1998; 20(1):80-7. PubMed ID: 9522106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Scrotal testosterone patches: a good addition to therapeutic options for hypogonadal men].
    Asscheman H; Gooren LJ
    Ned Tijdschr Geneeskd; 2000 Apr; 144(18):847-50. PubMed ID: 10816775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allergic contact dermatitis from transdermal buprenorphine.
    Vander Hulst K; Parera Amer E; Jacobs C; Dewulf V; Baeck M; Pujol Vallverdú RM; Giménez-Arnau A; Tennstedt D; Goossens A
    Contact Dermatitis; 2008 Dec; 59(6):366-9. PubMed ID: 19076888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of modifications of the traditional patch test in assessing the chemical irritation potential of feminine hygiene products.
    Farage MA; Meyer S; Walter D
    Skin Res Technol; 2004 May; 10(2):73-84. PubMed ID: 15059174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cumulative skin irritation test of sanitary pads in sensitive skin and normal skin population.
    Farage MA; Maibach H
    Cutan Ocul Toxicol; 2007; 26(1):37-43. PubMed ID: 17464747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence assessment of a single 5 mg/day testosterone transdermal system versus two 2.5 mg/day systems in hypogonadal men.
    Wilson DE; Meikle AW; Boike SC; Fairless AJ; Etheredge RC; Jorkasky DK
    J Clin Pharmacol; 1998 Jan; 38(1):54-9. PubMed ID: 9597560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers.
    Schmid-Grendelmeier P; Pokorny R; Gasser UE; Richarz U
    Curr Med Res Opin; 2006 Mar; 22(3):501-9. PubMed ID: 16574034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy.
    Wilson DE; Kaidbey K; Boike SC; Jorkasky DK
    Clin Ther; 1998; 20(2):299-306. PubMed ID: 9589821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone treatment comes of age: new options for hypogonadal men.
    Nieschlag E
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):275-81. PubMed ID: 16918944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin reactions in a phase 3 study of a testosterone topical solution applied to the axilla in hypogonadal men.
    Muram D; Melby T; Alles Kingshill E
    Curr Med Res Opin; 2012 May; 28(5):761-6. PubMed ID: 22458919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.